Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, June 24, 2022
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
[ Fri, Jun 24th 2022
] - WOPRAI
Etzer Darout Initiated (YMAB) at Buy and Held Target at $27 on, Jun 24th, 2022
Etzer Darout of BMO Capital, Initiated "Y-mAbs Therapeutics, Inc." (YMAB) at Buy and Held Target at $27 on, Jun 24th, 2022.
Etzer has made no other calls on YMAB in the last 4 months.
There is 1 other peer that has a rating on YMAB. Out of the 1 peers that are also analyzing YMAB, 0 agree with Etzer's Rating of Hold.
This is the rating of the analyst that currently disagrees with Etzer
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $63 on, Monday, February 28th, 2022
